Source: Virtual Congress 2020 – Translational therapeutic advances
Disease area: Interstitial lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. Chung (Taipei, Taiwan), M. Chen (Taipei, Taiwan), J. Tsai (Taipei, Taiwan), C. Hsieh (Taipei, Taiwan). Profibrotic implication of platelet-activating factor in tuberculous pleural effusion. 3356

Member's Comments

No comment yet.

Related content which might interest you: The role of vascular endothelial growth factor in tuberculous and parapneumonic pleural effusions Source: Annual Congress 2008 - Pleural diseases and interventions Year: 2008 Vascular endothelial growth factor (VEGF) in malignant and tuberculous pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001 Pleural fluid interleukin-10 level in the diagnosis of tuberculous effusions Source: Eur Respir J 2002; 20: Suppl. 38, 581s Year: 2002 Role of C-reactive protein in discriminating complicated and uncomplicated parapneumonic effusion from malignant and tuberculous pleural effusion Source: Virtual Congress 2021 – Clinical problems associated with cough, pleura and respiratory health status Year: 2021 Neutrophil-predominant effusion as a predictive factor for outcome in tuberculous pleurisy Source: International Congress 2018 – Pulmonary tuberculosis: long term complications, rehabilitation and challenges Year: 2018 Diagnostic value of interleukin-12 p40 in tuberculous pleural effusions Source: Eur Respir J 2009; 33: 816-820 Year: 2009 Interelukin-17A is elevated in parapneumonic pleural effusions and is associated with neutrophils and VEGF Source: Eur Respir J 2006; 28: Suppl. 50, 551s Year: 2006 Value of chitotriosidase enzyme activity in discrimination of tuberculous pleurisy from malignant pleural effusion Source: Annual Congress 2010 - Extrapulmonary tuberculosis Year: 2010 Pentraxin-3: A novel biomarker for the differentiation of parapneumonic effusion and malignant pleural effusion Source: Annual Congress 2012 - Novelties in clinical management of thoracic diseases: from diaphragm to pleura Year: 2012 Prognostic features of residual pleural thickening after parapneumonic pleural effusion Source: Eur Respir J 2002; 20: Suppl. 38, 605s Year: 2002 Tuberculous pleural effusion Source: Eur Respir J 2003; 22: Suppl. 45, 152s Year: 2003 Predictors of residual pleural opacity in tuberculous pleurisy Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007 Can VEGF be used in differential diagnosis of pleural effusions? Source: Eur Respir J 2007; 30: Suppl. 51, 565s Year: 2007 Diagnostic value of IL-8 in differentiating between exudative and transudative pleural effusion Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008 Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012 C-reactive protein in differentiation between tuberculous and malignant pleural effusions Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 Talc mediates angiostasis in malignant pleural effusions via endostatin induction Source: Eur Respir J 2007; 29: 761-769 Year: 2007 Host-derived osteopontin is important for malignant pleural effusion formation Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 Osteopontin is important for malignant pleural effusion formation Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009 Empyema and parapneumonic pleural effusion. Prognostic factors about 109 patients Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009